Our mission is to improve the lives of people everywhere through innovative vaccines and medicines. To do that, we apply new techniques to overcome barriers and accelerate progress. We never settle. Our deep expertise in disease pathways helps us take aim at smart targets, while our unique technologies empower us to develop drugs, biologics, and genomic medicines with the potential to transform the practice of medicine.
As of 31 March 2022, our R&D pipeline includes 91 clinical-stage projects, 34 of which are in phase 3 or have been submitted to regulatory authorities for approval. These projects represent new molecular entities as well as existing therapeutics being investigated for additional indications, or different formulations.
We use the most advanced technology platforms to pioneer new, innovative approaches to preventing diseases, or stopping them in their tracks.
Immunology & Inflammation
Our long-term commitment to treating inflammatory conditions is built on a deep understanding of disease, from its dynamic in a single immune cell to its impact on a patient's life. By following the science and committing to perpetual innovation, we’re accelerating our ambitious programs and building a rich pipeline of potential first- and best-in-class medicines.
With deep expertise in immuno-oncology and molecular oncology, our R&D teams have doubled down on difficult-to-treat cancers of the breast, lung, and blood. Thanks to cutting-edge tools like AI, synthetic biology, NANOBODY® technology, and antibody–drug conjugates, our teams are developing powerful precision therapeutics, designed to meet the specific needs of patients.
Patient insights and outstanding science drive our development of new therapeutics for people with neurological disorders. Using revolutionary technologies, our teams are developing targeted, potentially disease-modifying therapies for people with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The goal: to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.
Rare Blood Disorders
We’re determined to change the standard of care for people who are affected by rare blood disorders, and to find answers for people living with diseases for which no treatment is available. To do that, we’re building on a legacy of innovation that stems from the development of the first extended half-life clotting factors for treating hemophilia A and B, branching out to the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), and cutting-edge R&D in cold agglutinin disease.
We’re proud of our legacy in lysosomal storage disorders: a group of rare, genetic conditions caused by enzyme deficiencies. Working closely with patient communities, we’ve been developing pioneering medicines for Fabry, Gaucher, and Pompe diseases, and advancing toward new treatments for patients with acid sphingomyelinase deficiency (ASMD) and GM2 gangliosidoses (Tay-Sachs disease, AB variant, and Sandhoff disease).
To help stop the spread of infectious diseases, our R&D teams develop vaccine antigens: molecules that trigger the immune system to fight pathogens. We use data science to profile harmful bacteria and viruses, and a range of proprietary technologies to take aim at their vulnerabilities. We never stop innovating. We constantly pursue progress, turning science into immunizations that help protect people and communities around the world.
MAT-GLB-2200597 v 1.0 | March 2022